Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells

BioFactors

Volumn 28, Issue 3-4, 2006, Pages 159-168

  Jung, Jae In ^a   Chung, Eunkyung ^a   Seon, Mi Ra ^a   Shin, Hyun Kyung ^a   Kim, Eun Ji ^a   Lim, Soon Sung ^a   Chung, Won Yoon ^b   Park, Kwang Kyun ^b   Park, Jung Han Yoon ^a  

^a Hallym University   (South Korea)

^b Yonsei University College of Dentistry   (South Korea)

Author keywords

Akt; ErbB signaling; ERK 1 2; Isoliquiritigenin; Phosphatidylinositol 3 kinase; Prostate cancer cells

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; HEREGULIN BETA; ISOLIQUIRITIGENIN; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CULTURE MEDIUM; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; PATHOPHYSIOLOGY; PROSTATE TUMOR;

ALLIUM ASCALONICUM; GLYCYRRHIZA; RATTUS;

ANIMALS; ANTICARCINOGENIC AGENTS; CHALCONES; MALE; NEUREGULIN-1; PROSTATIC NEOPLASMS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 34250353135     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520280302     Document Type: Article

References (38)

1. M. Alimandi, A. Romano, M.C. Curia, R. Muraro, P. Fedi, S.A. Aaronson, P.P. Di Fiore and M.H. Kraus, Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas, Oncogene 10 (1995), 1813-1821.
2. I. Alroy and Y. Yarden, The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions, FEBS Lett 410 (1997), 83-86.
3. M. Baba, R. Asano, I. Takigami, T. Takahashi, M. Ohmura, Y. Okada, H. Sugimoto, T. Arika, H. Nishino and T. Okuyama, Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis, Biol Pharm Bull 25 (2002), 247-250.
4. B.F. Calvo, A.M. Levine, M. Marcos, Q.F. Collins, M.V. Iacocca, L.S. Caskey, C.W. Gregory, Y. Lin, Y.E. Whang, H.S. Earp and J.L. Mohler, Human epidermal receptor-2 expression in prostate cancer, Clin Cancer Res 9 (2003), 1087-1097.
5. K.L. Carraway, 3rd, S.P. Soltoff, A.J. Diamonti and L.C. Cantley, Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3, J Biol Chem 270 (1995), 7111-7116.
6. H.J. Cho, W.K. Kim, E.J. Kim, K.C. Jung, S. Park, H.S. Lee, A.L. Tyner and J.H. Park, Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line, Am J Physiol Gastrointest Liver Physiol 284 (2003), G996-1005.
7. A. Citri, K.B. Skaria and Y. Yarden, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Exp Cell Res 284 (2003), 54-65.
8. Z. Culig, A. Hobisch, A. Hittmair, H. Peterziel, C. Radmayr, G. Bartsch, A.C. Cato and H. Klocker, Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol Histopathol 12 (1997), 781-786.
9. Z. Culig, A. Hobisch, M.V. Cronauer, C. Radmayr, A. Hittmair, J. Zhang, M. Thurnher, G. Bartsch and H. Klocker, Regulation of prostatic growth and function by peptide growth factors, Prostate 28 (1996), 392-405.
10. S.R. Datta, A. Brunet and M.E. Greenberg, Cellular survival: a play in three Akts, Genes Dev 13 (1999), 2905-2927.
11. S.S. El Sheikh, J. Domin, P. Abel, G. Stamp and N. Lalani el, Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF, Neoplasia 6 (2004), 846-853.
12. D.L. Falls, Neuregulins: functions, forms, and signaling strategies, Exp Cell Res 284 (2003), 14-30.
13. A.W. Grasso, D. Wen, C.M. Miller, J.S. Rhim, T.G. Pretlow and H.J. Kung, ErbB kinases and NDF signaling in human prostate cancer cells, Oncogene 15 (1997), 2705-2716.
14. R.T. Greenlee, T. Murray, S. Bolden and P.A. Wingo, Cancer statistics, 2000, CA Cancer J Clin 50 (2000), 7-33.
15. C.W. Gregory, Y.E. Whang, W. McCall, X. Fei, Y. Liu, L.A. Ponguta, F.S. French, E.M. Wilson and H.S. Earp, 3rd, Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth, Clin Cancer Res 11 (2005), 1704-1712.
16. D. Hanahan and R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000), 57-70.
17. T. Holbro, G. Civenni and N.E. Hynes, The ErbB receptors and their role in cancer progression, Exp Cell Res 284 (2003), 99-110.
18. T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas, 3rd, and N.E. Hynes, The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation, Proc Natl Acad Sci USA 100 (2003), 8933-8938.
19. Y.L. Hsu, P.L. Kuo, L.T. Lin and C.C. Lin, Isoliquiritigenin inhibits cell proliferation and induces apoptosis in human hepatoma cells, Planta Med 71 (2005), 130-134.
20. K. Iwashita, M. Kobori, K. Yamaki and T. Tsushida, Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells, Biosci Biotechnol Biochem 64 (2000), 1813-1820.
21. J.I. Jung, S.S. Lim, H.J. Choi, H.J. Cho, H.K. Shin, E.J. Kim, W.Y. Chung, K.K. Park and J.H. Park, Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells, J Nutr Biochem (2005).
22. M. Kanazawa, Y. Satomi, Y. Mizutani, O. Ukimura, A. Kawauchi, T. Sakai, M. Baba, T. Okuyama, H. Nishino and T. Miki, Isoliquiritigenin inhibits the growth of prostate cancer, Eur Urol 43 (2003), 580-586.
23. I.H. Koumakpayi, J.S. Diallo, C. Le Page, L. Lessard, M. Gleave, L.R. Begin, A.M. Mes-Masson and F. Saad, Expression and nuclear localization of ErbB3 in prostate cancer, Clin Cancer Res 12 (2006), 2730-2737.
24. Y.H. Kwon, A. Jovanovic, M.S. Serfas, H. Kiyokawa and A.L. Tyner, P21 functions to maintain quiescence of p27-deficient hepatocytes, J Biol Chem 277 (2002), 41417-41422.
25. H.Y. Leung, J. Weston, W.J. Gullick and G. Williams, A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma, Br J Urol 79 (1997), 212-216.
26. J.C. Lyne, M.F. Melhem, G.G. Finley, D. Wen, N. Liu, D.H. Deng and R. Salup, Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro, Cancer J Sci Am 3 (1997), 21-30.
27. J. Ma, N.Y. Fu, D.B. Pang, W.Y. Wu and A.L. Xu, Apoptosis induced by isoliquiritigenin in human gastric cancer MGC-803 cells, Planta Med 67 (2001), 754-757.
28. G. Makin and C. Dive, Apoptosis and cancer chemotherapy, Trends Cell Biol 11 (2001), S22-26.
29. J. Mendelsohn and J. Baselga, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol 21 (2003), 2787-2799.
30. N. Mendoza, G.L. Phillips, J. Silva, R. Schwall and D. Wickramasinghe, Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer, Cancer Res 62 (2002), 5485-5488.
31. K.M. Nicholson and N.G. Anderson, The protein kinase B/Akt signalling pathway in human malignancy, Cell Signal 14 (2002), 381-395.
32. M.A. Olayioye, R.M. Neve, H.A. Lane and N.E. Hynes, The ErbB signaling network: receptor heterodimerization in development and cancer, Embo J 19 (2000), 3159-3167.
33. R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B.J. Ratzkin, M. Sela and Y. Yarden, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, Embo J 15 (1996), 2452-2467.
34. T. Takahashi, N. Takasuka, M. Iigo, M. Baba, H. Nishino, H. Tsuda and T. Okuyama, Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development, Cancer Sci 95 (2004), 448-453.
35. Y. Yarden and M.X. Sliwkowski, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol 2 (2001), 127-137.
36. Y. Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities, Eur J Cancer 37(Suppl 4) (2001), S3-8.
37. S. Yamamoto, E. Aizu, H. Jiang, T. Nakadate, I. Kiyoto, J.C. Wang and R. Kato, The potent anti-tumor-promoting agent isoliquiritigenin, Carcinogenesis 12 (1991), 317-323.
38. S. Yamazaki, T. Morita, H. Endo, T. Hamamoto, M. Baba, Y. Joichi, S. Kaneko, Y. Okada, T. Okuyama, H. Nishino and A. Tokue, Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma, Cancer Lett 183 (2002), 23-30.